Dai Jiabao, Lu Yanfeng, Zou Zhiqing, Wu Zhouquan
Department of Anesthesiology, the NO.2 People's Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China.
Psychopharmacology (Berl). 2025 Feb;242(2):285-295. doi: 10.1007/s00213-024-06673-y. Epub 2024 Aug 22.
Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive effects of subanesthetic doses esketamine have been observed in treatment-resistant depression, the response to this medication in patients experiencing depression following surgery has not been consistent. Building upon the known impact of anesthesia on brain function, we have formulated a hypothesis suggesting that the timing of esketamine administration in relation to anesthesia may significantly affect its efficacy in managing postoperative depression. The aim of this study was to investigate the effect of esketamine administered at different time points before and after anesthesia.
Our randomized, double-blind, controlled study involved 120 patients undergoing laparoscopic bariatric surgery, randomly divided into three groups. Group Post- ESK received an intravenous injection of esketamine at a dose of 0.2 mg/kg after anesthesia induction. Group Pre- ESK received the same esketamine dosage 2 h prior to anesthesia induction. Group Placebo served as the control group and received a 0.9% saline solution after induction. The primary outcome measures of the study were depression scores as measured by Patient Health Questionnaire-9 (PHQ-9) and plasma brain-derived neurotrophic factor (BDNF) levels.
On the first postoperative day, the PHQ-9 scores, incidence and severity of postoperative depression in the Pre-ESK group were significantly lower than those in the Post-ESK and placebo groups (P < 0.05). Additionally, plasma BDNF levels in the Pre-ESK group were significantly higher than those in the Post-ESK and placebo groups (P < 0.05). Notably, there was a negative correlation between PHQ-9 scores and plasma BDNF levels.
Our study supports the potential for subanesthetic dose esketamine to alleviate postoperative depression symptoms following laparoscopic bariatric surgery, and anesthetic drugs have a significant effect on its efficacy. The use of subanesthetic dose esketamine after anesthesia does not improve postoperative depression symptoms in patients undergoing laparoscopic bariatric surgery, while the use of sub-anesthetic dose esketamine before anesthesia can improve postoperative depression symptoms.
先前的研究报告了关于艾氯胺酮治疗术后抑郁疗效的相互矛盾的结果。虽然在难治性抑郁症中已观察到亚麻醉剂量艾氯胺酮的积极作用,但手术患者对这种药物的反应并不一致。基于麻醉对脑功能的已知影响,我们提出了一个假设,即艾氯胺酮给药时间与麻醉的关系可能会显著影响其治疗术后抑郁的疗效。本研究的目的是调查在麻醉前后不同时间点给予艾氯胺酮的效果。
我们的随机、双盲、对照研究纳入了120例行腹腔镜减肥手术的患者,随机分为三组。术后艾氯胺酮组在麻醉诱导后静脉注射剂量为0.2mg/kg的艾氯胺酮。术前艾氯胺酮组在麻醉诱导前2小时接受相同剂量的艾氯胺酮。安慰剂组作为对照组,诱导后接受0.9%的生理盐水。本研究的主要结局指标是通过患者健康问卷-9(PHQ-9)测量的抑郁评分和血浆脑源性神经营养因子(BDNF)水平。
术后第一天,术前艾氯胺酮组的PHQ-9评分、术后抑郁的发生率和严重程度显著低于术后艾氯胺酮组和安慰剂组(P<0.05)。此外,术前艾氯胺酮组的血浆BDNF水平显著高于术后艾氯胺酮组和安慰剂组(P<0.05)。值得注意的是,PHQ-9评分与血浆BDNF水平之间存在负相关。
我们的研究支持亚麻醉剂量艾氯胺酮减轻腹腔镜减肥手术后术后抑郁症状的潜力,并且麻醉药物对其疗效有显著影响。麻醉后使用亚麻醉剂量艾氯胺酮并不能改善腹腔镜减肥手术患者的术后抑郁症状,而麻醉前使用亚麻醉剂量艾氯胺酮可以改善术后抑郁症状。